CLH enters its Q1 2026 earnings call — scheduled for May 6 — on a strong footing on price, with the stock up nearly 10% over the past month to $306.20. The real story this week is a notable shift in how both options traders and the analyst community are positioning around that catalyst.
Options market sentiment has grown noticeably more cautious. The put/call ratio has climbed to roughly 0.99, more than 1.2 standard deviations above its 20-day mean of 0.69. That is a meaningful jump: as recently as early April, the ratio was running at 0.41 as call-dominated positioning prevailed. Since mid-April, demand for downside protection has risen sharply. The ratio is not near its 52-week high of 3.96, so this is not panic hedging — but the directional shift ahead of May 6 is hard to ignore.
Short interest tells a very different story, and the contrast matters. Bears have been retreating. SI has fallen roughly 31% over the past month and now amounts to just 1.5% of the free float — near the lowest readings of the year. The lending market is equally relaxed: availability is wide, borrow costs have barely moved, holding around 0.45% annualised with only a modest uptick on the week. This is not a stock facing any short-side pressure. The ORTEX short score of 29.7 confirms it — well below the midpoint on a 0-100 scale, indicating minimal bearish conviction in the positioning data.
Analyst activity has been one-sided in the right direction. Every firm that touched CLH in the past six weeks raised its price target. Citigroup upgraded from Neutral to Buy on April 8, lifting its target to $346. Goldman Sachs moved its target to $306 from $268 on the same day, though it held Neutral. Truist (Buy, target $325) and Baird (Outperform, target $350) both lifted numbers last week. The consensus mean target sits at $318 — modest upside from current levels, but the direction of travel across the Street has been uniformly positive. The analyst recommendation differential ranks in the 94th percentile of the universe, which reflects just how lopsided that bullish lean has become. EPS momentum is strong too, with the 90-day rank in the 76th percentile and the 12-month forward EPS growth expectation in the 89th percentile — underpinning the target-lift cycle.
The ownership picture adds a layer of context worth noting. Founder and longtime executive Alan McKim trimmed his position by roughly 211,000 shares as of mid-March, leaving him with just over 4.2% of shares outstanding. A cluster of executive sales also took place on March 13, involving the Co-CEO, CFO, President/CEO, and several EVPs — all at prices near $289. These are disclosed plan sales rather than distressed selling, but the breadth of the sell cluster at the same price and date is worth registering. On the institutional side, the top three holders — Wellington, BlackRock, and Vanguard — all nudged positions modestly higher through March, while Lone Pine Capital initiated a new position of 1.38 million shares in Q4 2025.
The most recent comparable earnings event, in February, saw CLH gain 4.6% on the day and 6.3% over the following week after reporting. With options positioning now more defensive than it was in February — and short interest much lower — the setup heading into May 6 reflects less a bearish bet than a hedged stance around a stock that has already re-rated considerably. What to watch: whether Q1 results and management commentary on PFAS remediation demand and the Kimball incinerator ramp-up justify the target upgrades that have arrived ahead of the print.
See the live data behind this article on ORTEX.
Open CLH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
